Monday, January 06, 2020 12:04:46 PM
Monday, 09/09/19 04:37:10 PM
Re: Jack2479 post# 243386 0
Post # of 258532
Thanks Jack. I missed that very important detail in Cognate's PR.
Since 2002, Cognate has serviced autologous and allogeneic products in various stages of development from preclinical to Phase 3, and most recently in pivotal Phase 3 with FDA pre-approval inspection preparation.
https://www.globenewswire.com/news-release/2019/08/07/1898347/0/en/Caladrius-Biosciences-and-Cognate-BioServices-Establish-Manufacturing-Agreement-for-Phase-3-Confirmatory-Pivotal-Clinical-Trial-of-CLBS14-in-No-option-Refractory-Disabling-Angina.html
flipper44 Member Level Sunday, 09/15/19 08:44:26 PM
Re: flipper44 post# 243437 0
Post # of 258536
Correction:
Cognate prepared for the pre-approval inspection. They do not conduct the inspection, regulators do. We do not know if that's been done, but it is possible it has (It typically takes seven days), because Cognate is already talking about their past pre-approval inspection preparation. Although, typically complete BLA filed first before inspection....who knows with rolling BLA.
Here is an image I found on the process (not specific to Cognate).
Note: Cognate already reached GMP approval for Europe as well by June of this year.
I'd assume we are at least as far as that last star to the bottom right in the process.

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
